Evaluation of the endocrine activity of 2,4,6-tribromophenol, benzanthrone and benzophenone-2 based on Appendix 7.8-5 of REACH guidance document

Karen Duis, Henrik Holbech, Yohana M. Velasco-Santamaría

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

Resumé

Within a project funded by the German Federal Environment Agency, the practicability of Appendix 7.8-5 of REACH guidance document R.7b was evaluated using three case study substances. Shortcomings in the guidance were identified. An assessment of potential endocrine activity in aquatic vertebrates was performed for benzanthrone, 2,4,6-tribromophenol and benzophenone-2, which differ in the amount of available data. Main focus was on effects on the estrogen/androgen axis. Potential endocrine activity was evaluated based on literature data and additional in vitro and in vivo testing. In the following, the main findings and the conclusions with regard to Appendix 7.8-5 are highlighted. (1) For benzanthrone, no binding to the estrogen receptor (ER) is predicted using QSAR methods, but potential metabolites with strong affinity to the ER were identified. At present, the endocrine activity of such metabolites is not considered in Appendix 7.8-5. Since many in vitro assays have limited metabolic capacity, this is a shortcoming for substances, for which no in vivo data are available. (2) Reporter gene assays indicate weak ER agonism of benzanthrone; in vitro results on androgen receptor mediated effects are conflicting. In such cases, additional guidance would be required to clarify in which cases further in vitro or in vivo tests should be performed. Currently, Appendix 7.8-5 provides little guidance on how to evaluate potential concern in cases where only QSAR and/or in vitro data are available. (3) 2,4,6-Tribromophenol has highest activity in tests, which are not part of most in vitro testing batteries (e.g. a sulfotransferase and a transthyretin binding assay). Hence, such effects might be overlooked. Generally, there appears to be a considerable risk that endocrine activity is not identified for data-poor substances, given that the initial assessment of endocrine activity according to Appendix 7.8-5 is only based on an evaluation of available information.
OriginalsprogEngelsk
Publikationsdato24. okt. 2012
Antal sider1
StatusUdgivet - 24. okt. 2012
Begivenhed6th SETAC Europe Special Science Symposium: Environmental Endocrine Disruptor Testing and Evaluations. Current and Future Developments - Hotel Marviaux, Brussel, Belgien
Varighed: 24. okt. 201225. okt. 2012

Workshop

Workshop6th SETAC Europe Special Science Symposium
LokationHotel Marviaux
LandBelgien
ByBrussel
Periode24/10/201225/10/2012

Fingeraftryk

Quantitative Structure-Activity Relationship
Prealbumin
Androgen Receptors
Reporter Genes
Vertebrates
In Vitro Techniques
2,2',4,4'-tetrahydroxybenzophenone
Estrogens

Citer dette

Duis, K., Holbech, H., & Velasco-Santamaría, Y. M. (2012). Evaluation of the endocrine activity of 2,4,6-tribromophenol, benzanthrone and benzophenone-2 based on Appendix 7.8-5 of REACH guidance document. Abstract fra 6th SETAC Europe Special Science Symposium, Brussel, Belgien.
Duis, Karen ; Holbech, Henrik ; Velasco-Santamaría, Yohana M. / Evaluation of the endocrine activity of 2,4,6-tribromophenol, benzanthrone and benzophenone-2 based on Appendix 7.8-5 of REACH guidance document. Abstract fra 6th SETAC Europe Special Science Symposium, Brussel, Belgien.1 s.
@conference{1f7d4ff181c94403b568796c3cc76e3a,
title = "Evaluation of the endocrine activity of 2,4,6-tribromophenol, benzanthrone and benzophenone-2 based on Appendix 7.8-5 of REACH guidance document",
abstract = "Within a project funded by the German Federal Environment Agency, the practicability of Appendix 7.8-5 of REACH guidance document R.7b was evaluated using three case study substances. Shortcomings in the guidance were identified. An assessment of potential endocrine activity in aquatic vertebrates was performed for benzanthrone, 2,4,6-tribromophenol and benzophenone-2, which differ in the amount of available data. Main focus was on effects on the estrogen/androgen axis. Potential endocrine activity was evaluated based on literature data and additional in vitro and in vivo testing. In the following, the main findings and the conclusions with regard to Appendix 7.8-5 are highlighted. (1) For benzanthrone, no binding to the estrogen receptor (ER) is predicted using QSAR methods, but potential metabolites with strong affinity to the ER were identified. At present, the endocrine activity of such metabolites is not considered in Appendix 7.8-5. Since many in vitro assays have limited metabolic capacity, this is a shortcoming for substances, for which no in vivo data are available. (2) Reporter gene assays indicate weak ER agonism of benzanthrone; in vitro results on androgen receptor mediated effects are conflicting. In such cases, additional guidance would be required to clarify in which cases further in vitro or in vivo tests should be performed. Currently, Appendix 7.8-5 provides little guidance on how to evaluate potential concern in cases where only QSAR and/or in vitro data are available. (3) 2,4,6-Tribromophenol has highest activity in tests, which are not part of most in vitro testing batteries (e.g. a sulfotransferase and a transthyretin binding assay). Hence, such effects might be overlooked. Generally, there appears to be a considerable risk that endocrine activity is not identified for data-poor substances, given that the initial assessment of endocrine activity according to Appendix 7.8-5 is only based on an evaluation of available information.",
author = "Karen Duis and Henrik Holbech and Velasco-Santamar{\'i}a, {Yohana M.}",
year = "2012",
month = "10",
day = "24",
language = "English",
note = "6th SETAC Europe Special Science Symposium : Environmental Endocrine Disrupter testing and evaluation ; Conference date: 24-10-2012 Through 25-10-2012",

}

Duis, K, Holbech, H & Velasco-Santamaría, YM 2012, 'Evaluation of the endocrine activity of 2,4,6-tribromophenol, benzanthrone and benzophenone-2 based on Appendix 7.8-5 of REACH guidance document', 6th SETAC Europe Special Science Symposium, Brussel, Belgien, 24/10/2012 - 25/10/2012.

Evaluation of the endocrine activity of 2,4,6-tribromophenol, benzanthrone and benzophenone-2 based on Appendix 7.8-5 of REACH guidance document. / Duis, Karen; Holbech, Henrik; Velasco-Santamaría, Yohana M.

2012. Abstract fra 6th SETAC Europe Special Science Symposium, Brussel, Belgien.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

TY - ABST

T1 - Evaluation of the endocrine activity of 2,4,6-tribromophenol, benzanthrone and benzophenone-2 based on Appendix 7.8-5 of REACH guidance document

AU - Duis, Karen

AU - Holbech, Henrik

AU - Velasco-Santamaría, Yohana M.

PY - 2012/10/24

Y1 - 2012/10/24

N2 - Within a project funded by the German Federal Environment Agency, the practicability of Appendix 7.8-5 of REACH guidance document R.7b was evaluated using three case study substances. Shortcomings in the guidance were identified. An assessment of potential endocrine activity in aquatic vertebrates was performed for benzanthrone, 2,4,6-tribromophenol and benzophenone-2, which differ in the amount of available data. Main focus was on effects on the estrogen/androgen axis. Potential endocrine activity was evaluated based on literature data and additional in vitro and in vivo testing. In the following, the main findings and the conclusions with regard to Appendix 7.8-5 are highlighted. (1) For benzanthrone, no binding to the estrogen receptor (ER) is predicted using QSAR methods, but potential metabolites with strong affinity to the ER were identified. At present, the endocrine activity of such metabolites is not considered in Appendix 7.8-5. Since many in vitro assays have limited metabolic capacity, this is a shortcoming for substances, for which no in vivo data are available. (2) Reporter gene assays indicate weak ER agonism of benzanthrone; in vitro results on androgen receptor mediated effects are conflicting. In such cases, additional guidance would be required to clarify in which cases further in vitro or in vivo tests should be performed. Currently, Appendix 7.8-5 provides little guidance on how to evaluate potential concern in cases where only QSAR and/or in vitro data are available. (3) 2,4,6-Tribromophenol has highest activity in tests, which are not part of most in vitro testing batteries (e.g. a sulfotransferase and a transthyretin binding assay). Hence, such effects might be overlooked. Generally, there appears to be a considerable risk that endocrine activity is not identified for data-poor substances, given that the initial assessment of endocrine activity according to Appendix 7.8-5 is only based on an evaluation of available information.

AB - Within a project funded by the German Federal Environment Agency, the practicability of Appendix 7.8-5 of REACH guidance document R.7b was evaluated using three case study substances. Shortcomings in the guidance were identified. An assessment of potential endocrine activity in aquatic vertebrates was performed for benzanthrone, 2,4,6-tribromophenol and benzophenone-2, which differ in the amount of available data. Main focus was on effects on the estrogen/androgen axis. Potential endocrine activity was evaluated based on literature data and additional in vitro and in vivo testing. In the following, the main findings and the conclusions with regard to Appendix 7.8-5 are highlighted. (1) For benzanthrone, no binding to the estrogen receptor (ER) is predicted using QSAR methods, but potential metabolites with strong affinity to the ER were identified. At present, the endocrine activity of such metabolites is not considered in Appendix 7.8-5. Since many in vitro assays have limited metabolic capacity, this is a shortcoming for substances, for which no in vivo data are available. (2) Reporter gene assays indicate weak ER agonism of benzanthrone; in vitro results on androgen receptor mediated effects are conflicting. In such cases, additional guidance would be required to clarify in which cases further in vitro or in vivo tests should be performed. Currently, Appendix 7.8-5 provides little guidance on how to evaluate potential concern in cases where only QSAR and/or in vitro data are available. (3) 2,4,6-Tribromophenol has highest activity in tests, which are not part of most in vitro testing batteries (e.g. a sulfotransferase and a transthyretin binding assay). Hence, such effects might be overlooked. Generally, there appears to be a considerable risk that endocrine activity is not identified for data-poor substances, given that the initial assessment of endocrine activity according to Appendix 7.8-5 is only based on an evaluation of available information.

M3 - Conference abstract for conference

ER -

Duis K, Holbech H, Velasco-Santamaría YM. Evaluation of the endocrine activity of 2,4,6-tribromophenol, benzanthrone and benzophenone-2 based on Appendix 7.8-5 of REACH guidance document. 2012. Abstract fra 6th SETAC Europe Special Science Symposium, Brussel, Belgien.